RGS 365
Alternative Names: RGS-365Latest Information Update: 12 May 2022
At a glance
- Originator RNAGENE
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 19 Apr 2022 Preclinical trials in Solid tumours in South Korea (Parenteral) (RNAGENE pipeline, April 2022)